Dr. Tamagnan is an Associate Professor Adjunct, Department of Psychiatry, and the CEO of XingImaging and Research Scientist at Xuanwu Hospital in Beijing. Dr. Tamagnan provides leadership and expert knowledge to colleagues to design and coordinate experiments for radiolabeling the tracers and for developing them into a radiopharmaceutical suitable for human administration. He is also responsible of the IND submission and working with the clinical team to validate the radiopharmaceutical. He has over 20 years of industrial and academic experience in the research and development of radiopharmaceuticals labeled with short-lived gamma-emitting radionuclides. Dr. Tamagnan is an active member of the nuclear medicine research community over the past 20 years and has been involved in the evaluation of over 70 CNS PET and SPECT imaging agents in human aimed at the development of improved diagnosis and treatment of neurologic and psychiatric conditions. He is a physician sponsor of over 35 INDs.
Dr. Gu has over 15 years of experience in clinical studies on early prediction and management of Parkinson's disease. She worked as project manager for multiple national and international cooperation projects, including MJFF projects, and played an important role in the setup and management for the first clinical center and specialist training system on Parkinson’s disease & Movement disorders in China. In 2018, Dr. Gu joined XingImaging China, started to build up the National PET network in China, and set up the standardized SOP for clinical operations for PET studies. In 2018, Dr. Gu joined XingImaging China, started to build up the National PET network in China, and set up the standardized SOP for clinical operations for PET studies.
In June 2019, Rebecca took on the role of COO after serving as a consultant for XingImaging since its inception. Prior to that she worked for more than 15 years with XingImaging’s principals at Molecular NeuroImaging (MNI) and the Institute for Neurodegenerative Disorders (IND). During her time at MNI and IND Rebecca helped build the companies’ regulatory affairs and quality groups, writing policies and procedures, developing structure with business awareness and regulatory rigor. During the second half of her career with these organizations, she headed up operations which expanded her experience to contract and budget review, company system oversight, business development, and employment management. She is a licensed attorney in the State of Connecticut focusing her part-time private practice on regulatory, trusts and estates, administrative and contract law.
David joined XingImaging since its inception to manage the radiochemistry and quality assurance oversight activities. David is an expert in radiochemistry manufacturing and control applied to clinical trial imaging and drug development. He completed a PhD in medicinal organic chemistry prior to being introduced to radiochemistry during a post-doctoral study at Yale University. He then joined Molecular Neuroimaging and directed the chemistry and technology transfer department for over 10 years.
George was trained as a radiochemist from Beijing Normal University and received a PhD. During this period, he was co-trained at the departments of Radiology and Pharmacology in the University of Pennsylvania. for two years. Then he worked as a postdoctoral researcher at Xuanwu Hospital Capital Medical University, during which he received training on GMP production of radiopharmaceutical at Molecular NeuroImaging, LLC (MNI). His research focuses on the development and transformation of radiopharmaceuticals. He has prepared and evaluated a number of compounds with novel structures and participated in the development of the BNU-F2 radiopharmaceutical synthesizer. He has also participated in the clinical transformation of new PET imaging tracers in China, including clinical research in hospitals and IND application, counting the β-amyloid tracer 18F-Florbetapir, vesicles monoamine transporter II imaging agent 18F-FP-DTBZ. He has extensive knowledge of about the regulations and production process of radiopharmaceuticals. Currently, he is mainly engaged in the development, production and laboratory management of PET imaging tracers.
Copyright © 2021 XingImaging, LLC - All Rights Reserved.